Page last updated: 2024-11-10

bay u9773

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

BAY u9773: a leukotriene C4 antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

BAYu9773 : A dicarboxylic acid that is that is (7E,9E,11Z,14Z)-icosa-7,9,11,14-tetraenoic acid substituted by a hydroxy group at position 4S and a (4-carboxyphenyl)sulfanediyl group at 5R. It is a dual cysteinyl leukotriene receptor antagonist that acts at the CysLT1 and CysLT2 receptors (IC50 = 0.44 and 0.30 muM, respectively). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5311015
CHEMBL ID285954
CHEBI ID167654
SCHEMBL ID1446016
MeSH IDM0194021

Synonyms (22)

Synonym
6(r)-(4-carboxyphenylthio)-5(s)-hydroxy-7(e),9(e),11(e),14(z)-eicosatetraenoic acid
bay-u 9773
CHEBI:167654
154978-38-8
4-{[(4s,5r,6e,8e,10z,13z)-1-carboxy-4-hydroxynonadeca-6,8,10,13-tetraen-5-yl]sulfanyl}benzoic acid
bayu9773
6-(4'-carboxyphenylthio)-5-hydroxy-7,9,11,14-eicosatetraenoic acid
bay u9773
bay-u9773
CHEMBL285954 ,
SCHEMBL1446016
benzoic acid,4-[[(1r,2e,4e,6z,9z)-1-[(1s)-4-carboxy-1-hydroxybutyl]-2,4,6,9-pentadecatetraen-1-yl]thio]-
gtpl3381
4-[[(1r,2e,4e,6z,9z)-1-[(1s)-4-carboxy-1-hydroxybutyl]-2,4,6,9-pentadecatetraen-1-yl]thio]benzoic acid
AKOS024457452
bdbm50033096
4-(((4s,5r,6e,8e,10z,13z)-1-carboxy-4-hydroxynonadeca-6,8,10,13-tetraen-5-yl)thio)benzoic acid
Q27074916
4-[(4s,5r,6e,8e,10z,13z)-1-carboxy-4-hydroxynonadeca-6,8,10,13-tetraen-5-yl]sulfanylbenzoic acid
4-(((4s,5r,6e,8e,10z,13z)-1-carboxy-4-hydroxynonadeca-6,8,10,13-tetraen-5-yl)thio)benzoicacid
benzoic acid, 4-[[(1r,2e,4e,6z,9z)-1-[(1s)-4-carboxy-1-hydroxybutyl]-2,4,6,9-pentadecatetraen-1-yl]thio]-
HY-107609

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Pretreatment with BAY u9773 or leukotriene D4, caused concentration-dependent rightward displacement of the concentration-response curve for leukotriene D4."( Agonist and antagonist activities of the leukotriene analogue BAY u9773 in guinea pig lung parenchyma.
Dahlén, SE; Rosenqvist, U; Wikström Jonsson, E, 1998
)
0.86

Dosage Studied

ExcerptRelevanceReference
"In different groups of portally perfused control and cirrhotic rat livers, the following were analyzed: a portal perfusion pressure (PP) dose-response curve to LTD4; the effects on PP caused by either vehicle, the selective 5-lipoxygenase inhibitor AA-861, the selective Cys-LT1 receptor antagonist MK-571, or the dual Cys-LT1 and Cys-LT2 receptor antagonist BAY u9773; and immunohistochemistry for 5-lipoxygenase in liver sections of cirrhotic and control livers."( 5-lipoxygenase inhibition reduces intrahepatic vascular resistance of cirrhotic rat livers: a possible role of cysteinyl-leukotrienes.
Bosch, J; Claria, J; García-Pagán, JC; Graupera, M; Massaguer, A; Rodés, J; Titos, E, 2002
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
leukotriene antagonistA drug designed to prevent leukotriene synthesis or activity by blocking binding at the receptor level.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
dicarboxylic acidAny carboxylic acid containing two carboxy groups.
secondary alcoholA secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it.
organic sulfideCompounds having the structure RSR (R =/= H). Such compounds were once called thioethers.
benzoic acidsAny aromatic carboxylic acid that consists of benzene in which at least a single hydrogen has been substituted by a carboxy group.
polyunsaturated fatty acidAny fatty acid containing more than one double bond. Acids in this group are reported to have cardioprotective effects; and levels are lowered in chronic fatigue syndrome.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cysteinyl leukotriene receptor 2Homo sapiens (human)IC50 (µMol)0.30000.00102.405210.0000AID1171360
Cysteinyl leukotriene receptor 1Homo sapiens (human)IC50 (µMol)0.44000.00030.948710.0000AID1171359
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (15)

Processvia Protein(s)Taxonomy
immune responseCysteinyl leukotriene receptor 2Homo sapiens (human)
leukotriene signaling pathwayCysteinyl leukotriene receptor 2Homo sapiens (human)
neuropeptide signaling pathwayCysteinyl leukotriene receptor 2Homo sapiens (human)
inflammatory response to antigenic stimulusCysteinyl leukotriene receptor 1Homo sapiens (human)
calcium ion transportCysteinyl leukotriene receptor 1Homo sapiens (human)
chemotaxisCysteinyl leukotriene receptor 1Homo sapiens (human)
defense responseCysteinyl leukotriene receptor 1Homo sapiens (human)
cell surface receptor signaling pathwayCysteinyl leukotriene receptor 1Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationCysteinyl leukotriene receptor 1Homo sapiens (human)
respiratory gaseous exchange by respiratory systemCysteinyl leukotriene receptor 1Homo sapiens (human)
positive regulation of angiogenesisCysteinyl leukotriene receptor 1Homo sapiens (human)
positive regulation of vasoconstrictionCysteinyl leukotriene receptor 1Homo sapiens (human)
establishment of localization in cellCysteinyl leukotriene receptor 1Homo sapiens (human)
positive regulation of glial cell proliferationCysteinyl leukotriene receptor 1Homo sapiens (human)
leukotriene signaling pathwayCysteinyl leukotriene receptor 1Homo sapiens (human)
cellular response to hypoxiaCysteinyl leukotriene receptor 1Homo sapiens (human)
neuropeptide signaling pathwayCysteinyl leukotriene receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
leukotriene receptor activityCysteinyl leukotriene receptor 2Homo sapiens (human)
protein bindingCysteinyl leukotriene receptor 2Homo sapiens (human)
cysteinyl leukotriene receptor activityCysteinyl leukotriene receptor 2Homo sapiens (human)
G protein-coupled peptide receptor activityCysteinyl leukotriene receptor 2Homo sapiens (human)
leukotriene receptor activityCysteinyl leukotriene receptor 1Homo sapiens (human)
cysteinyl leukotriene receptor activityCysteinyl leukotriene receptor 1Homo sapiens (human)
G protein-coupled peptide receptor activityCysteinyl leukotriene receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
cellular_componentCysteinyl leukotriene receptor 2Homo sapiens (human)
plasma membraneCysteinyl leukotriene receptor 2Homo sapiens (human)
plasma membraneCysteinyl leukotriene receptor 2Homo sapiens (human)
plasma membraneCysteinyl leukotriene receptor 1Homo sapiens (human)
membraneCysteinyl leukotriene receptor 1Homo sapiens (human)
plasma membraneCysteinyl leukotriene receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID1171359Antagonist activity at human CysLT1 receptor expressed in CHO cells assessed as inhibition of LTD4-inudced intracellular calcium influx preincubated for 30 mins before LTD4 addition by Fura2-AM assay2014ACS medicinal chemistry letters, Nov-13, Volume: 5, Issue:11
Discovery of Highly Potent Dual CysLT1 and CysLT2 Antagonist.
AID1171360Antagonist activity at human CysLT2 receptor expressed in HEK293 cells assessed as inhibition of LTD4-inudced intracellular calcium influx preincubated for 30 mins before LTD4 addition by Fura2-AM assay2014ACS medicinal chemistry letters, Nov-13, Volume: 5, Issue:11
Discovery of Highly Potent Dual CysLT1 and CysLT2 Antagonist.
AID1346092Rat CysLT2 receptor (Leukotriene receptors)1994European journal of pharmacology, Nov-03, Volume: 264, Issue:3
BAY u9773, a novel antagonist of cysteinyl-leukotrienes with activity against two receptor subtypes.
AID1346073Human CysLT2 receptor (Leukotriene receptors)2000Molecular pharmacology, Dec, Volume: 58, Issue:6
Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist.
AID1346031Human CysLT1 receptor (Leukotriene receptors)2010British journal of pharmacology, May, Volume: 160, Issue:2
Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT(2)) receptor.
AID1346073Human CysLT2 receptor (Leukotriene receptors)1992The Journal of pharmacology and experimental therapeutics, Nov, Volume: 263, Issue:2
A second cysteinyl leukotriene receptor in human lung.
AID1346073Human CysLT2 receptor (Leukotriene receptors)2010British journal of pharmacology, May, Volume: 160, Issue:2
Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT(2)) receptor.
AID1346073Human CysLT2 receptor (Leukotriene receptors)2000The Journal of biological chemistry, Sep-29, Volume: 275, Issue:39
Characterization of the human cysteinyl leukotriene 2 receptor.
AID1346031Human CysLT1 receptor (Leukotriene receptors)2000Molecular pharmacology, Dec, Volume: 58, Issue:6
Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist.
AID1346073Human CysLT2 receptor (Leukotriene receptors)2011The Journal of pharmacology and experimental therapeutics, Dec, Volume: 339, Issue:3
A selective cysteinyl leukotriene receptor 2 antagonist blocks myocardial ischemia/reperfusion injury and vascular permeability in mice.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (36)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's7 (19.44)18.2507
2000's19 (52.78)29.6817
2010's10 (27.78)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 15.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index15.95 (24.57)
Research Supply Index3.66 (2.92)
Research Growth Index4.43 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (15.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (2.70%)5.53%
Reviews2 (5.41%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other34 (91.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]